carbamates has been researched along with Arterial Diseases, Carotid in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients." | 5.11 | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. ( Esposito, K; Giugliano, D; Marfella, R; Nappo, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Nappo, F | 1 |
| Marfella, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
1 trial available for carbamates and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |